Skip to main content
editorial
. 2016 Feb;5(1):115–119. doi: 10.3978/j.issn.2218-6751.2016.01.06

Table 2. Recommended targets for clinically meaningful trials in NSCLC [modified after (20)].

NSCLC histology OS (base line, months) Primary endpoint: improvement of OS Secondary endpoint: 1-year-survival Secondary endpoint: improvement of PFS
Squamous 10–11 2.5–3 months (HR =0.77–0.80) 44–53% 4 months
Non-squamous 14 3.25–4 months (HR =0.76–0.80) 53–61% 3 months

NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; HR, hazard ratio.